Biohaven (NYSE:BHVN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Biohaven (NYSE:BHVN) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other equities analysts have also issued reports about the stock. Needham & Company LLC set a $11.00 price target on shares of Biohaven in a research report on Monday, June 29th. Morgan Stanley upped their price objective on shares of Biohaven from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Robert W. Baird set a $48.00 price objective on shares of Biohaven in a report on Thursday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biohaven in a research note on Friday, August 28th. Finally, HC Wainwright reissued a “neutral” rating and set a $10.00 target price on shares of Biohaven in a report on Thursday, September 10th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.25.

Biohaven Stock Performance

Shares of BHVN stock opened at $14.46 on Friday. The business has a fifty day moving average of $13.49 and a 200 day moving average of $12.16. Biohaven has a 1 year low of $7.48 and a 1 year high of $18.57. The company has a debt-to-equity ratio of 21.23, a current ratio of 4.73 and a quick ratio of 4.73. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of -3.12 and a beta of 1.35.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15). As a group, research analysts expect that Biohaven will post -3.33 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BHVN. Sigma Planning Corp grew its stake in shares of Biohaven by 43.1% during the 3rd quarter. Sigma Planning Corp now owns 19,944 shares of the company’s stock worth $266,000 after purchasing an additional 6,008 shares during the period. Sterling Capital Management LLC increased its holdings in shares of Biohaven by 847.5% during the 3rd quarter. Sterling Capital Management LLC now owns 4,444 shares of the company’s stock valued at $59,000 after purchasing an additional 3,975 shares in the last quarter. Inspire Investing LLC lifted its stake in shares of Biohaven by 2.4% in the 3rd quarter. Inspire Investing LLC now owns 47,089 shares of the company’s stock valued at $629,000 after purchasing an additional 1,113 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lifted its stake in shares of Biohaven by 12.9% in the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 17,500 shares of the company’s stock valued at $234,000 after purchasing an additional 2,000 shares during the period. Finally, Opaleye Management Inc. purchased a new stake in Biohaven during the second quarter worth $1,159,000. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Biohaven Company Profile

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.